Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
<h4>Background</h4>The stem cell factor receptor, KIT, is a target for the treatment of cancer, mastocytosis, and inflammatory diseases. Here, we characterise the in vitro and in vivo profiles of masitinib (AB1010), a novel phenylaminothiazole-type tyrosine kinase inhibitor that targets...
Main Authors: | Patrice Dubreuil, Sébastien Letard, Marco Ciufolini, Laurent Gros, Martine Humbert, Nathalie Castéran, Laurence Borge, Bérengère Hajem, Anne Lermet, Wolfgang Sippl, Edwige Voisset, Michel Arock, Christian Auclair, Phillip S Leventhal, Colin D Mansfield, Alain Moussy, Olivier Hermine |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2009-09-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19789626/?tool=EBI |
Similar Items
-
Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.
by: Martine Humbert, et al.
Published: (2010-03-01) -
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
by: Vermersch Patrick, et al.
Published: (2012-06-01) -
Long-term survival analysis of masitinib in amyotrophic lateral sclerosis
by: Jesus S. Mora, et al.
Published: (2021-07-01) -
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.
by: Daniela Silva Moura, et al.
Published: (2011-01-01) -
Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial
by: Davidescu L, et al.
Published: (2022-06-01)